Cyclophosphamide, bortezomib,anddexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

238Citations
Citations of this article
116Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Bortezomib has shown great promise in the treatment of amyloid light-chain (AL) amyloidosis. We present our experience of 43 patients with AL amyloidosis who received cyclophosphamide, bortezomib, and dexamethasone (CVD) upfront or at relapse. Of these, 74% had cardiac involvement and 46% were Mayo Cardiac Stage III. The overall hematologic response rate was 81.4%, including complete response (CR) in 41.9% and very good partial response with > 90% decrease in difference between involved/uninvolved light chain (VGPR-dFLC) in 51.4%. Patients treated upfront had higher rates of CR (65.0%) and VGPR-dFLC (66.7%). The estimated 2-year progression-free survival was 66.5% for patients treated upfront and 41.4% for relapsed patients. Those attaining a CR or VGPR-dFLC had a significantly better progression-free survival (P = .002 and P = .026, respectively). The estimated 2-year overall survival was 97.7% (94.4% in Mayo Stage III patients). CVD is a highly effective regimen producing durable responses in AL amyloidosis; the deep clonal responses may overcome poor prognosis in advanced-stage disease. © 2012 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Venner, C. P., Lane, T., Foard, D., Rannigan, L., Gibbs, S. D. J., Pinney, J. H., … Wechalekar, A. D. (2012). Cyclophosphamide, bortezomib,anddexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood, 119(19), 4387–4390. https://doi.org/10.1182/blood-2011-10-388462

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free